JBL Your CRDMO Partner in Science
JA
EN
  • About Us
    • Vision, Values & Promise
    • Company Overview
    • Leadership Team
    • Our Facilities
    • Contact Us
  • Services
    • Integrated Drug Discovery
      • Target Identification
      • Target Validation
      • HIT Identification
      • HIT to Lead
      • Lead Optimization
      • Candidate Selection
    • Chemistry
      • Synthetic Chemistry
      • Medicinal Chemistry
      • Analytical Chemistry
      • Computational Chemistry
      • Specialised Chemistry-COE
      • Oligonucleotide Offerings
    • Structural Biology
      • Custom Protein Production
      • SPR
      • Crystallography
      • SBDD
    • Assay Biology
      • In-Vitro Biology
      • Target Validation
      • Overexpression Models
      • Bio-Chemical Assay, D&S
      • Cell Based Assay, D&S
      • Mode of Action Studies
      • Biomarker Evaluation
    • DMPK
      • Physicochemical Properties
      • In-Vitro ADME
      • In-Vivo Pharmacokinetics
      • Drug Interactions
      • Metabolite Identification
      • Bioanalysis
      • Large Molecule Bioanalysis
    • Computational Chemistry (CADD)
      • Virtual Screening
      • LBDD
      • Insilico FBDD
      • Chemoinformatics
    • Pharmacology
      • Oncology Animal Models
      • Inflammation Animal Models
      • Pain and Neuroscience Animal Models
      • Diabetes & Metabolic Disorders Animal Models
    • Toxicology
      • GLP & Non GLP Studies
      • Acute Toxicity
      • Subchronic Toxicity
      • Genetic Toxicity
      • Safety Pharmacology
      • Toxicokinetics
    • CDMO
      • Process R&D Services
      • Analytical Development
      • Process Safety Studies
      • Polystate Capabilities
      • Technology Transfer
      • Early to Late Phase Supplies
      • GLP, Non-GMP and GMP Mfg.
    • API
      • API Capabilities
      • Product List
    • For more information reach us at: bd@jubilantbiosys.com
  • Target Approaches
    • Kinases
    • Non-Kinase Enzymes
    • GPCRs & Ion Channels
    • Transcription Factors
    • Immune Regulators
    • Target Protein Degradation
    • RNA Small Molecule Drugs
  • Our Commitment
    • EHS
    • Corporate Governance
    • Corporate Social Responsibility
    • Sustainability
    • Quality & IP
  • Resources
    • News
    • Press Releases
    • Events
    • Publications
    • Whitepapers
    • Brochures
    • Webinars
    • Customer Testimonials
  • Careers
    • Job Opportunities
    • Returning Indian Talent
    • Policies
    • Recruitment Fraud Advisory
    • Group Ombudsperson

Category: Publications

Targeting HIF-2α as Therapy for Advanced Cancers

Posted on September 25, 2019December 5, 2024 by ddAdmin
Targeting HIF-2α as Therapy for Advanced Cancers

Authors: Thanabal Murugesan, Gurukumari Rajajeyabalachandran, Swetha Kumar, Shruthi Nagaraju, Sooriya Kumar Jegatheesan

Journal: Drug Discovery Today, Volume 23, Number 7, July 2018.

Posted in Publications

Across Geographies – From the Lens of a Project Manager from a Healthcare CRO

Posted on September 25, 2019December 5, 2024 by ddAdmin
Across Geographies – From the Lens of a Project Manager from a Healthcare CRO

Author: Bhuvaneswari Jayaraman

Presented at: Project Management Practitioners Conference 2018, Bangalore

Posted in Publications

Synthetic Analogues of the Parasitic Worm Product ES-62 Reduce Disease Development in In Vivo Models of Lung Fibrosis

Posted on September 25, 2019December 5, 2024 by ddAdmin
Synthetic Analogues of the Parasitic Worm Product ES-62 Reduce Disease Development in In Vivo Models of Lung Fibrosis

Authors: Colin J.Sucklinga, SambuddhoMukherjee, Abedawn .Khalafa, Ashwini Narayan, Fraser J.Scott, Sonal Khare, Saravanakumar Dhakshinamoorthy, Margaret M.Harnett, William Harnett

Journal: Acta Tropica 185 (2018) 212–218

Posted in Publications

PLK4: A Link between Centriole Biogenesis and Cancer

Posted on September 24, 2019December 5, 2024 by ddAdmin
PLK4: A Link between Centriole Biogenesis and Cancer

Authors: Radhika Radha Maniswami, Seema Prashanth, Archana Venkataramana Karanth, Sindhu Koushik, Hemalatha Govindaraj, Ramesh Mullangi, Sriram Rajagopal & Sooriya Kumar Jegatheesan

Posted in Publications

Crystal Structures of Monkey and Mouse Nicotinamide N-methyltransferase (NNMT) bound with End Product, 1-methyl Nicotinamide

Posted on September 24, 2019December 5, 2024 by ddAdmin
Crystal Structures of Monkey and Mouse Nicotinamide N-methyltransferase (NNMT) bound with End Product, 1-methyl Nicotinamide

Authors: Swaminathan S, Birudukota S, Thakur MK, Parveen R, Kandan S, Juluri S, Shaik S, Anand NN, Burri RR, Kristam R, Hallur MS, Rajagopal S, Schreuder H, Langer T, Rudolph C, Ruf S, Dhakshinamoorthy S, Gosu R, Kannt A

Posted in Publications

PAD4: Pathophysiology, Current Therapeutics and Future Perspective in Rheumatoid Arthritis

Posted on September 24, 2019December 5, 2024 by ddAdmin
PAD4: Pathophysiology, Current Therapeutics and Future Perspective in Rheumatoid Arthritis

Authors: Sindhu Koushik, Nivedita Joshi, Shruthi Nagaraju, Sameer Mahmood, Krishna Mudeenahally, Ramya Padmavathy, Sooriya Kumar Jegatheesan, Ramesh Mullangi and Sriram Rajagopal

Posted in Publications

Co-crystal structures of PTK6: With Dasatinib at 2.24 Å, with novel imidazo[1,2-a]pyrazin-8-amine derivative inhibitor at 1.70 Å resolution

Posted on September 24, 2019December 5, 2024 by ddAdmin
Co-crystal structures of PTK6: With Dasatinib at 2.24 Å, with novel imidazo[1,2-a]pyrazin-8-amine derivative inhibitor at 1.70 Å resolution

Authors: Manish Kumar Thakur, Swarnakumari Bridukota, Srinivasan Swaminathan, Sivarama Krishna Battula, Sarvanan Vadivelu, Rajiv Tyagi and Ramchandraiah Gosu

Posted in Publications

Emerging Role of SETDB1 as a Therapeutic Target

Posted on September 24, 2019December 5, 2024 by ddAdmin
Emerging Role of SETDB1 as a Therapeutic Target

Authors: Archana Venkataramana Karanth, Radhika Radha Maniswami, Seema Prashanth, Hemalatha Govindaraj, Ramya Padmavathy, Sooriya Kumar Jegatheesan, Ramesh Mullangi and Sriram Rajagopal

Posted in Publications

Posts navigation

Newer posts
JBL Footer

Jubilant Biosys is a Contract Research, Development and Manufacturing Organization in India providing comprehensive drug discovery, contract research and manufacturing services in partnership with leading healthcare companies worldwide.

For Business Queries
bd@jubilantbiosys.com
For Career Related Queries
careers@jubilantbiosys.com

Company

  • Manufacturing Facilities
  • Contact
  • Careers
  • News

Our Locations

    R&D Centers
  • Noida, India
  • Greater Noida, India
  • Bengaluru, India
Manufacturing Plant
  • Nanjangud, India
Sales Offices
  • Asia
  • Europe
  • North America

Services

  • Discovery Chemistry
  • Integrated Drug Discovery
  • CDMO
  • Digital

Get in touch

© 2025 Jubilant Biosys Ltd. A Jubilant Pharmova Limited Company

  • Policies
  • Jubilant Group
  • Sitemap
  • Disclaimer
  • Payment

Request For Information

We appreciate all business enquiries, If you'd like our Business Development team to contact you, please complete this form.